A new radioactive drug for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new radioactive drug (177Lu-AB-3PRGD2) that targets a protein called integrin αvβ3 found on many solid tumors. It is for people whose cancer has not responded to or has come back after several standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of solid tumor cancer that has not responded to or has come back after multiple treatments
- You have at least one tumor that is larger than 1 cm (about the size of a pea) or a lymph node larger than 1.5 cm
- You are able to walk and take care of yourself, even if you need some help (ECOG score 0 to 3)
- You have not had major surgery in the last 4 weeks, or do not plan to have surgery in the next 6 weeks
- You are not pregnant or breastfeeding, and you are willing to use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a targeted radioactive medicine (177Lu-AB-3PRGD2) can shrink or control tumors that strongly match a specific target seen on special scans. It may help people whose current standard treatments are not working or are no longer working.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This trial tests a new radioactive drug (177Lu-TATE-RGD) that targets two specific markers on tumor cells. It is for people whose cancer has not responded to standard treatments and whose tumors show high levels of these markers on a PET scan.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Hear when a new Refractory Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.